Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MorphoSys Strengthens European Patent Position on Anti-CD19 Cancer Program MOR208

Published: Tuesday, December 03, 2013
Last Updated: Tuesday, December 03, 2013
Bookmark and Share
New patent has a scheduled expiry date in 2027.

MorphoSys AG has announced that the European Patent Office has granted a patent covering the Company's cancer compound MOR208.

The new patent (EP2383297) covers the antibody's protein and nucleic acid sequences as well as pharmaceutical compositions comprising the same.

The new patent has a scheduled expiry date in 2027, not including any potential patent office or regulatory extensions, and is licensed to MorphoSys AG from Xencor, Inc.

Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG, commented: "MOR208 will be a key focus area for our development activities in the years to come and thus patent protection in the most relevant markets is of significant importance. Today's patent complements a new US patent covering the MOR208 antibody, which we announced a few weeks ago."

MOR208 is a humanized monoclonal antibody that targets the antigen CD19 for treatment of B cell malignancies and autoimmune diseases.

The antibody has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.

MOR208 has shown encouraging signs of preliminary anti-tumor activity and an acceptable safety and tolerability profile in a Phase 1/2a trial in patients with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The study results showed an overall response rate of 29.6% (according to IWCLL 2008 criteria) based on the safety population of the trial (n=27).

MorphoSys is conducting Phase 2 clinical trials of MOR208 in patients with non-Hodgkin's lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MorphoSys Publishes Update on MOR202 in Multiple Myeloma
First data from final 16 mg/kg dose escalation cohort and combination with immunomodulatory drugs show encouraging activity.
Thursday, September 24, 2015
MorphoSys Provides an Update on its Proprietary Development Portfolio
Lead cancer program MOR208 to be examined in numerous combination studies in hematological cancers.
Thursday, September 10, 2015
MorphoSys and Immatics Enter Strategic Alliance in Immuno-oncology
Collaboration aims to develop novel antibody-based therapies targeting tumor-associated peptides derived from intracellular proteins.
Tuesday, August 25, 2015
MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study
Phase 1 study to evaluate the novel oncology immunotherapeutic MOR209/ES414 for prostate cancer.
Wednesday, March 11, 2015
MorphoSys Announces Additional Clinical Trial of MOR208
Phase 2 study in CLL will evaluate MOR208 in combination with lenalidomide.
Wednesday, December 11, 2013
MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208
New patent covers the antibody's protein sequence.
Tuesday, October 22, 2013
MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208
Extended treatment resulted in higher overall response rate.
Tuesday, October 08, 2013
MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202
New patent covers functional properties of anti-CD38 antibodies.
Thursday, December 06, 2012
MorphoSys Signs Three-Year Protein Engineering Alliance on Slonomics Technology
License agreement covers the delivery of multiple Slonomics®-based DNA libraries.
Monday, February 27, 2012
MorphoSys Signs Long-term Alliance with Pfizer on Sloning Technology Platform
Sloning's Slonomics® platform will be installed at Pfizer's subsidiary Rinat Neuroscience Corp. for fabrication of gene and protein libraries.
Sunday, December 12, 2010
MorphoSys Licenses HuCAL PLATINUM® Antibody Library to Shionogi in Research Partnership
Shionogi expands its current research license to cover the use of MorphoSys's HuCAL PLATINUM technology in drug discovery.
Friday, January 29, 2010
MorphoSys Nominates First Pre-Development Program in Antibody Collaboration
MorphoSys has exercised its first option to participate in the development of a therapeutic antibody program within its collaboration with Novartis.
Wednesday, September 24, 2008
MorphoSys Opens new Facilities in Oxford, UK
UK Minister of Science Malcolm Wicks inaugurates MorphoSys’ 2,200 square meters UK headquarters in North Oxford.
Monday, January 22, 2007
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Personality Traits, Psychiatric Disorders Linked to Specific Genomic Locations
Researchers have unearthed genetic correlations between personality traits and psychiatric disorders.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Gene-Editing Improves Vision in Blind Rats
Scientists developed a targeted gene-replacement technique that can modify genes in both dividing and non-dividing cells in living animals.
Gene Editing Yields Tomatoes That Ripen Weeks Earlier
Research team develop method to make tomato plants flower and ripen fruit two weeks faster than current growth rates.
Exploring the Genome of the River Blindness Parasite
Researchers have decoded the genome of the parasite that causes the skin and eye infection known as river blindness.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Unexpected Role for Epigenetic Enzymes in Cancer
Researchers use epigenetics to identify the role of an enzyme family as regulators of genetic message interpretation in yeast.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!